COVID-19-induced cytokine storm demonstrates the devastating effects of immune dysregulation
- Clinical research , COVID 19 , Inflammation , Protein biomarkers
- Read time: 8 minutes
The biological process of a cytokine release storm is a generalized inflammatory response to a pathogen (most recently associated with COVID-19 mortality), or a reaction to a cell-therapy treatment or autoimmune disease (such as primary hemophagocytic lymphohistiocytosis, a severe systemic inflammatory syndrome). Described here are the interaction between the triggered driver cells (both adaptive T-cells and antigen-presenting cells) and the important cytokine players involved (including IL-18, TNF, IL-1b, IFN-gamma, IL-6 and IL-17).
The inflammatory devastation of a cytokine release storm
“Cytokine storm” is an umbrella term including several kinds of immune dysregulation that can lead to multi-organ failure and death. Characterized by systemic inflammation, organ-specific symptoms range from respiratory (acute respiratory distress syndrome or ARDS, pulmonary edema), neurological (confusion, seizures or delirium), renal (kidney disfunction or kidney failure) to liver (elevated liver enzymes, cholestasis, liver failure) and circulatory failure (cytopenia, anemia, endothelial damage). In all cases of cytokine storm there is an elevated level of cytokines and systemic inflammation.
Typically with infectious agents (whether bacterial or viral) there is a transition from an initial innate immune response (starting within hours of infection) to a suppression of this response, carefully balanced between mounting an effective response against the infection and minimizing the amount of collateral damage caused to different body tissues.
In cases of COVID-19, current available data suggest ~5 to ~11% of the severe cases of COVID-19, or about 2% of all COVID-19 infected patients[1] have elevated cytokine levels consistent with a cytokine storm. Another study compared cytokine levels of COVID-19 affected individuals to those infected with severe influenza, and found 4% of the cases of COVID-19-infected individuals had elevated cytokine levels.2
Other triggers of cytokine storm include chimeric antigen receptor T-cell therapy (known as CAR-T therapy), other pathogenic infections in addition to SARS-CoV-2 such as bacterial sepsis, cancer or autoinflammatory disorders such as EBV-associated hemophagocytic lymphohistiocytosis.
Cytokine storm first triggers a set of immune cells
Once triggered, the innate immune cells (monocytes, neutrophils and macrophages along with a host of other cell types such as dendritic cells and natural killer cells) recognize pathogens, release cytokines and ingest (phagocytose) the invading pathogens. Neutrophils, macrophages and NK cells are most often implicated in cytokine storm, producing excessive amounts of cytokines that are its hallmark.
The adaptive immune system, namely helper T-cells (Th1, Th2, Th9 and Th17, along with Cytotoxic T-Lymphocytes) exude cytokines specific to their cell type (for example Th17 produces IL-17, IL-21 and IL-22 targeting and recruiting neutrophils) to mount a specific response. Chemokines are intricately involved in recruiting specific cell types, including IL-8 (also called CXCL8), MCP-1 (CXCL2), MIP-1a (CCL3) and MIP-1b (CCL4).
The cytokines involved comprise a long list, with the main pro-inflammatory molecules including IL-6, IL-1, IL-17, IL-18, IL-33, IFN-g and GM-CSF. Balancing the inflammation response are anti-inflammatory molecules, including IL-10 and IL-1RA and anti-inflammatory cell types including Treg and mesenchymal stem cells.
A generalized cytokine response amplified into an inflammatory cytokine storm
It should be noted that the defining composition and threshold levels of inflammatory molecules in a cytokine storm has not yet been established. However, the list of the component molecules is long: nine interleukins (of which Interleukin-6, Interleukin-18, Interleukin-17 and Interleukin 1beta are key players). Other important cytokines are Tumor Necrosis Factor (TNF) and Interferon gamma (IFNg), as well as the chemokine IP-10 (CXCL10).. There are an additional six cytokines and three plasma proteins that all take part in an interacting network.
The list of nine interleukins, seven chemokines and three plasma proteins, along with their main roles, are listed in Table 1.3
Cytokine, Growth Factor | Function |
Interleukin 1 (IL-1) | proinflammatory, pyrogenic |
Interleukin 2 (IL-2) | T-cell growth factor |
Interleukin 6 (IL-6) | proinflammatory, pyrogenic, increase antibody production |
Interleukin 9 (IL-9) | activation of mast cells |
Interleukin 10 (IL-10) | anti-inflammatory cytokine, inhibit Th1 |
Interleukin 12 (IL-12) | Activate Th1 |
Interleukin 17 (IL-17) | Neutrophil inflammation |
Interleukin 18 (IL-18) | Proinflammatory, activation of Th1 |
Interleukin 33 (IL-33) | Proinflammatory, amplification of Th1 Th2 cells |
Interferon gamma (IFN-g) | Proinflammatory, activation of macrophages |
Tumor Necrosis Factor (TFN) | pyrogenic, increase vascularization |
Granulocyte macrophage colony stimulating factor (GM-CSF) | Proinflammatory |
Vascular endothelial growth factor (VEGF) | Increase vascularization |
Chemokines | |
Interleukin 8 (CXCL8) | Recruit neutrophils |
MIG (CXCL9) | Recruit Th1, NK and plasmacytoid dendritic cells |
IP-10 (CXCL10) | Recruit macrophages, Th1 and NK cells |
MCP-1 (CCL2) | Recruit Th2, monocytes, dendritic cells |
MIP-1α (CCL3) | Recruit macrophages, Th1, NK, dendritic cells, pyrogenic |
MIP-1β (CCL4) | Recruit macrophages, Th1, NK, dendritic cells |
BLC (CXCL13) | Recruit B cells, dendritic cells |
Plasma Proteins | |
C reactive protein (CRP) | Increases IL-8 and MCP-1 |
Complement | Contributes to tissue damage |
Ferritin | Primary cell storage of iron |
Table 1: List of cytokines, growth factors, chemokines and plasma proteins involved in cytokine storm. Adapted from reference 3.
The inflammatory responses of both innate and adaptive immune components act downstream on important signaling pathways that cause damage to tissues and organs. The four main pathways are MAPK, NF-kB, JAK-STAT3, and mTOR. The trigger (whether a pathogen or a CAR-T cell therapy treatment) may or may not be present; the levels of inflammation due to the cytokines and chemokines form an amplifying loop of cells producing these molecules, and recruiting additional cell types that in turn, produce additional cytokine and chemokine molecules.
Subsequent damage to organs such as the lung, liver and kidney leads to multiorgan failure.
Targeting cytokines and chemokines preceding severe COVID
Given the multifactorial nature of cytokine storms, involving both the innate and adaptive immune systems, any attempt at bringing back homeostasis for this intricate balance of many cell and molecular components poses a formidable challenge. There are several on-market drugs that inhibit specific components, such as anti-TNF (infliximab, trade name Remicade) or anti-Interleukin-6 (siltuximab, trade name Sylvant); these have been used in early attempts to treat cytokine storm but have been shown to be ineffective.4 Targeting the downstream signaling pathways, for example the JAK-STAT3 with JAK inhibitors such as ruxolitinib have also been attempted but were also ineffective.
As is often the case, further research into the drivers and mitigators of the amplification of cytokine signals is needed.
Olink® Target 48 Cytokine is the ideal protein biomarker panel with which to measure 45 cytokines and chemokines simultaneously. See the link below for further information.5
References
- RECOVERY Collaborative Group and Landry MJ et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 383(21):2030-2040. doi:10.1056/NEJMoa2022926
- Mudd PA and Ellebedy AH et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv. 2020 6(50):eabe3024. doi:10.1126/sciadv.abe3024
- Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020 383(23):2255-2273. doi:10.1056/NEJMra2026131
- Stone JH and Mansour MK et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020 383(24):2333-2344. doi:10.1056/NEJMoa2028836
- Olink Target 48 Cytokine Panel product information. https://www.olink.com/products-services/target/48-cytokine-panel/
Upgrade your inflammation research
Find out more about why protein biomarkers can transform your inflammation research.
How the proteome behaves in healthy individuals
Clinical research, Multiomics
To achieve the goal of precision medicine, not only do different molecular profiles need to be understood in disease populations, but they must also be understood in the context of healthy populations.
Key proteomics publications from 2020
Proteomics
Welcome to the first post of the all-new weekly Olink to Science! Our customer survey revealed that you would like to know more about the many publications, research, and other science happening at Olink, therefore this blog aims to do just that: keep you informed on the exciting science taking place with our technology.
Protein biomarkers are crucial in early detection of cancer
Clinical research, Oncology, Protein biomarkers
A central premise of precision medicine is to identify biomarkers indicative of disease transitions early on. This is especially important in cancer where early treatment intervention could increase a patient’s chance of survival and reduce the probability of cancer recurrence.
Using PEA and RNA-Seq to study disease pathology
Clinical research, Proteomics
The following study illustrates how transcriptomics and proteomics complement one another to clarify the pathology of a complex, and little understood disease. Atopic dermatitis (AD) is the most common chronic skin condition affecting up to 20% of children and 7-10% of adults, depending on the population.
Olink protein biomarker panel indicates fermented foods fight inflammation
Inflammation, Proteomics
Could food be used to fight chronic disease?
Study identifies proteins involved in immunotherapy response
Oncology, Proteomics
'Ultimately, it is all about understanding and treating patients better in the future.'
Proteins diagnostic of lung cancer up to 5 years before disease onset
Oncology
An earlier Olink to Science blog post covered some amazing research that found that certain blood protein biomarkers have the potential to predict cancer up to 3 years before diagnosis. This may also be the case for lung cancer, as detailed in a recent study by Dagnino and her colleagues, where elevated levels of CDCP1 were detected in participants of a cohort who later developed the disease.
Utilizing proteogenomics technology for novel drug target discovery
Drug discovery & development
High-throughput multiplexed proteomic technology is leading the way to the latest developments in pre-clinical disease analysis in drug discovery. The pharmaceutical industry is now increasing its efforts in the discovery of novel drug targets by using protein quantitative trait loci (pQTLs), which allows for a more confident inference of disease causality and associated protein regulation.
Developing a high-performance biomarker panel for Alzheimer’s disease
Clinical research, Neurology, Protein biomarkers
A simple search of the term ‘scourge of Alzheimer’s Disease’ brings up over half a million website hits. A major disease, about 15% of us that reach the age of 67 to 74, and 44% of those 75 to 84 will develop AD.
How proteomics helped diabetic kidney disease research advance
Clinical research, Proteomics
Dr. Krolewski and his team at the Harvard Medical School found 56 proteins to be significant in diabetic kidney disease patients. Potentially, these could serve as prognostic biomarkers for disease progression and treatment response. This is how adding proteomics to the methodologies elevated their research.
2947
Biomarker assays
~881 million
Protein data points generated
1182
Publications listed on website